<DOC>
	<DOC>NCT01350778</DOC>
	<brief_summary>The objective of this study is to evaluate effectiveness and safety of BioMatrix stent in the "real world" daily practice as compared with first-generation drug-eluting stents (sirolimus- or paclitaxel-eluting stents).</brief_summary>
	<brief_title>Evaluation of Effectiveness and Safety of BIOMATRIX Stent (IRIS-BIOMATRIX)</brief_title>
	<detailed_description>This study is a non-randomized, prospective, open-label registry to compare the efficacy and safety of BioMatrix stents versus first-generation drug-eluting stent (DES) in patients with coronary artery disease.</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>Patients receiving BioMatrix stents The patient or guardian agrees to the study protocol and the schedule of clinical followup, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethics Committee of the respective clinical site. Patients with a mixture of other DESs Terminal illness with life expectancy &lt;1 year Patients with cardiogenic shock</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Coronary artery disease requiring drug eluting stents</keyword>
</DOC>